BBIO - BridgeBio Pharma, Inc.

76.68
-0.070   -0.091%

Share volume: 1,650,339
Last Updated: 04-20-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$76.75
-0.07
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 15%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.07%
1 Month
10.17%
3 Months
-1.88%
6 Months
41.06%
1 Year
128.83%
2 Year
205.86%
Key data
Stock price
$76.68
P/E Ratio 
0.00
DAY RANGE
$75.71 - $77.26
EPS 
-$3.78
52 WEEK RANGE
$31.77 - $84.94
52 WEEK CHANGE
$124.34
MARKET CAP 
14.740 B
YIELD 
N/A
SHARES OUTSTANDING 
193.863 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-31-2025
BETA 
1.09
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,866,760
AVERAGE 30 VOLUME 
$1,611,405
Company detail
CEO: Neil Kumar
Region: US
Website: bridgebio.com
Employees: 400
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a stabilizer of transthyretin, or TTR.

Recent news